A New York Times article reviewing advances in technology, genetics, brain science and biology that may one day enable the Sylmar-based Second Sight Medical Products under the leadership of co-founder, president & CEO Robert Greenberg, Ph.D., M.D. (photo right), to reach a goal that long seemed unattainable: restoring sight... Read article

Neumedicines Inc. (Pasadena, CA) announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) exercised the first and second milestone-based options related to the Company's existing contract with BARDA to develop Neumedicines' lead therapeutic, HemaMax, as a treatment for acute radiation exposure. The milestone-based options are valued at $4.9 million, bringing the total funding provided thus far by BARDA to $8 million. The total contract award including the base contract and options is projected to yield over $13 million for the development of HemaMax as a radiomitigator.... Read more

The Calabasas-based Kythera presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. "ATX-101 shows promise for patients who are seeking a minimally invasive treatment for unwanted localized submental fat," said Kevin C. Smith, a Canadian investigator in both Phase 2 studies. "The significant reduction we saw in submental fat for patients treated with ATX-101 illustrates its potential as a safe, simple prescription aesthetic product" ....Read more

OrthAlign is a privately held medical device company that was established in the summer of 2008. The company is developing a line of computer assisted surgical devices that distill the critical features and benefits of large surgical navigation systems in a non invasive, disposable, palm sized solution with accompanying instrumentation. OrthAlign is seeking to fill these two positions:

A medical device  company creating a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa is filling the following positions:

 See more job announcements on our Linkedin Page

SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio